A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Caspofungin

Criteria

Inclusion Criteria:

• Patient has a low white cell count (less than 500/mm3) for at least 96 hours

• Patient is indian and is greater than 18 years of age

• Patient received chemotherapy for blood disorders and blood cancers

Exclusion Criteria:

• Patient has an invasive fungal infection

• Patient has a bacterial infection that is not controlled

• Patient has allergy to the class of antifungals of study drug

• Patient is not expected to survive at least 5 days

• Patient is pregnant or breast-feeding